Company Filing History:
Years Active: 2002
Title: Aida Inbal: Innovator in Antiplatelet Therapy
Introduction
Aida Inbal is a prominent inventor based in Hod-Hasharon, Israel. She has made significant contributions to the field of medical science, particularly in the development of antiplatelet agents. Her innovative work focuses on creating therapeutic methods to improve patient outcomes in thrombotic disorders.
Latest Patents
Aida Inbal holds a patent for an antiplatelet agent. This invention combines the unique antiplatelet effects of S-nitrosothiols with the antiadhesive properties of fragments of von Willebrand factor (vWF) in the A1 domain. The preferred molecules in her patent include a fragment of A1 (Ala 444-Asn 730) where arginine at position 545 is replaced by cysteine. This modification has been discovered to impair platelet adhesion and inhibit antithrombotic activity in vivo. The cysteine residue can be S-nitrosated to produce a novel molecule that has the potential to impair platelet adhesion, activation, and aggregation. This invention lays the groundwork for a new therapeutic method aimed at managing platelet responses following vascular injury or in other thrombotic disorders.
Career Highlights
Aida Inbal has established herself as a leading figure in her field through her innovative research and patent contributions. Her work has the potential to significantly impact the treatment of thrombotic disorders, showcasing her dedication to advancing medical science.
Collaborations
Aida collaborates with Joseph Loscalzo, a respected figure in the medical research community. Their partnership enhances the development and application of her innovative therapies.
Conclusion
Aida Inbal's contributions to antiplatelet therapy represent a significant advancement in medical innovation. Her work not only highlights her expertise but also promises to improve treatment options for patients with thrombotic disorders.